Champions Receives US Patent For Tubulin, SG410

US Patent and Trademark Office (USPTO) has issued a patent for the Champions Biotechnology’s (Champions) tubulin inhibitors, including its lead compound SG410.

Reportedly, US Patent No. 7,595,326 entitled Synthesis of Novel Tubulin Polymerisation Inhibitors: Benzoylphenylurea (BPU) Sulfur Analogs protects the company’s composition of matter, pharmaceutical composition, and method of treatment for SG410.

Doug Burkett, president of Champions, said: “This patent solidifies Champions’ intellectual property position on SG410. We believe that SG410, in the new Neowater formulation we developed, has the potential to significantly impact the treatment of cancer. SG410 is Champions’ first internal compound and is currently undergoing Biomerk Tumorgraft evaluation.

“The results of SG410 tests in our predictive platform are expected to be available soon. We are also actively evaluating high potential compounds to build our oncology drug pipeline and expect to in-license additional drugs in the near future. Studies suggest that evaluations of compounds through Biomerk Tumorgrafts will lead to more successful and efficient clinical development.”